NucliThera AS submitted a patent application and a trademark application in July 2026 in support of its RadiuMeta project. The filings form part of the company’s strategy to protect its innovations and establish a distinct identity for the project. RadiuMeta focuses on developing novel alpha-emitting therapies for metastatic cancer. By investing in intellectual property alongside…
Summary: The manuscript findings show that Betalutin had substantial antitumour activity, was well tolerated and had a manageable adverse event profile. The PARADIGME datashowed a trend towards better efficacy in patients treated with the 40/15 regimen compared with the 100/20 regimen. Patients with grade I–IIIa follicular lymphoma (FL) who had received at least two prior…
Thor Medical ASA has signed a five-year frame agreement to supply NucliThera AS with thorium-228 (Th-228). The isotope will be used in NucliThera’s development programs for hematological cancers. Led by Dr. Roy H. Larsen and Professor Emeritus Øyvind S. Bruland, NucliThera’s research team is advancing an early-stage development program targeting hematological cancers such as lymphoma…
NucliThera AS has engaged Ada Repetto-Llamazares as Chief Scientific Officer as of February 1, 2025.Ada Repetto-Llamazares, PhD, is an accomplished leader in radiopharmaceutical development, combining over 15 years of hands-on expertise in advancing radioligand therapies with a strong foundation in nuclear physics and dual PhDs—a PhD in radioligand therapy from the University of Oslo and…